预约演示
更新于：2025-05-08
Minocycline Hydrochloride
盐酸米诺环素
更新于：2025-05-08
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
首次获批日期 中国台湾 (1961-08-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C23H28ClN3O7 |
InChIKeyGLMUAFMGXXHGLU-VQAITOIOSA-N |
CAS号13614-98-7 |
关联
263
项与 盐酸米诺环素 相关的临床试验NCT01422148
Minocycline Plus Amiodarone Versus Amiodarone Alone for the Prevention of Atrial Fibrillation After Cardiac Surgery (MINA)
NCT06699966
Stony Brook Medicine Anti-Inflammatory Trial
NCT05605366
Minocycline in Neurocognitive Outcomes - Sickle Cell Disease
100 项与 盐酸米诺环素 相关的临床结果
登录后查看更多信息
100 项与 盐酸米诺环素 相关的转化医学
登录后查看更多信息
100 项与 盐酸米诺环素 相关的专利（医药）
登录后查看更多信息
11,101
项与 盐酸米诺环素 相关的文献（医药）2025-09-01JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
Identification of related substances in minocycline hydrochloride via 2D-LC-Q-TOF /MS
Article
作者: Jiang, Jing ; Hu, Zhaoliang ; Hang, Taijun ; Lu, Yuting ; Jiang, Li
Minocycline hydrochloride is a semisynthetic tetracycline derivative with a wide range of applications. The related substances significantly influence its efficacy and safety. However, the investigation of potential related substances in minocycline hydrochloride or its products remains incomplete. Herein, a reliable two-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry (2D-LC-Q-TOF/MS) method was developed for the separation and identification of the related substances in minocycline hydrochloride tablets. Seventeen related substances, including process-related substances and degradation products, were identified based on the chromatographic and mass spectrometric data. Notably, thirteen of these related substances were newly elucidated. Formation mechanisms of these related substances were proposed, and the degradation pathways of minocycline hydrochloride were systematically established. These findings are useful for the quality control of minocycline hydrochloride as well as other tetracycline drugs.
2025-08-01Journal of Environmental Sciences
Biotransformation of minocycline by a novel strain Kluyvera sp. DM13 isolated from municipal sludge: Performances, removal pathways, and toxicity
Article
作者: Jiang, Hui ; Ma, Xinting ; Lu, Jinsuo ; Yu, Mengzhu ; Chen, Xingdu ; Liu, Xin ; Jiang, Hao
Minocycline has been widely used in clinical treatment and its residues were considered to have environmental safety risks due to complex chemical structure. Therefore, it is necessary to find an efficient and environmentally friendly method to remove minocycline from the environment. This study screened and isolated a minocycline degrading strain DM13 from the activated sludge for municipal sewage pipeline, and optimized the biodegradation of minocycline by DM13 under various environmental conditions. The maximum biodegradation efficiency of 50 mg/L minocycline reached 93 % at 72 h with the temperature of 30 °C, the initial pH of 7.0, and the inoculation rate of 3 %. Two potential biotransformation pathways were proposed, including deamination, demethylation, and decarbonylation. The acute toxicity assessment showed that the biotransformation products of minocycline had lower toxicity than the parent compound. In addition, the first-generation tetracycline antibiotics could be removed, suggesting that strain DM13 has the potential for application in treating antibiotic wastewater.
2025-07-01SEPARATION AND PURIFICATION TECHNOLOGY
Investigation into the internal electronic channel and radical contribution in the in-situ H2O2 photosynthesis and concurrent pharmaceutical wastewater cleanup
作者: Zhu, Qiaohong ; Zhang, Yiwen ; Wang, Zijie ; Zeng, Xiaofei ; Zhuang, Fengze ; Qian, Yangzhu
Pharmaceutical wastewater purification is a paramount challenge, and the production and transportation of H2O2 remain safety concerns.Herein, novel 3-benzoylpropenoic acid was utilized as the electron acceptor linking with carbon nitride through the amide bond, realizing a delighted H2O2 generation of 4.29 mM mM g-1 cat. h-1 , together with a tetracycline removal efficiency of 89%, which can be attributed to the promoted charge transfer capacity and the strengthened surface adsorption of oxygen.Intriguingly, it is investigated that .O2- is an important factor for H2O2 synthesis, while .O2- and .OH both participate in pollutants treatment.Addnl., the applications in various pollutants further manifest the environmental adaptability and extensibility of the system.Addnl., the further introduction of iron ions enables the strengthened activation of H2O2 in a mild condition, thus accelerating the transformation of diclofenac into smaller mols.Such an investigation paves a promising way for the fabricating carbon nitride based systems with novel electron acceptor, and provide a mechanism guidance for the pollutants treatment paired with H2O2 synthesis.
100 项与 盐酸米诺环素 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 玫瑰痤疮 | 美国 | 2020-05-28 | |
| 寻常痤疮 | 美国 | 2006-05-08 | |
| 炭疽 | 日本 | 2002-03-06 | |
| 感染 | 中国 | 1992-01-01 | |
| 地方性斑疹伤寒 | 日本 | 1989-09-01 | |
| 鹦鹉热 | 日本 | 1985-11-05 | |
| 急性支气管炎 | 日本 | 1979-04-20 | |
| 细菌性阴道炎 | 日本 | 1979-04-20 | |
| 膀胱炎 | 日本 | 1979-04-20 | |
| 泪囊炎 | 日本 | 1979-04-20 | |
| 附睾炎 | 日本 | 1979-04-20 | |
| 淋病 | 日本 | 1979-04-20 | |
| 睑腺炎 | 日本 | 1979-04-20 | |
| 感染性肠炎 | 日本 | 1979-04-20 | |
| 子宫内感染 | 日本 | 1979-04-20 | |
| 颌骨炎症 | 日本 | 1979-04-20 | |
| 喉炎 | 日本 | 1979-04-20 | |
| 肺脓肿 | 日本 | 1979-04-20 | |
| 淋巴结炎 | 日本 | 1979-04-20 | |
| 乳腺炎 | 日本 | 1979-04-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 种植体周围炎 | 临床3期 | 美国 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 德国 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 瑞典 | 2012-04-01 | |
| 种植体周围炎 | 临床3期 | 英国 | 2012-04-01 | |
| 慢性牙周炎 | 临床3期 | 美国 | 2006-01-01 | |
| 侵袭性牙周炎 | 临床3期 | 美国 | 2004-01-01 | |
| 脓疱疮 | 临床2期 | 以色列 | 2010-08-01 | |
| 肌萎缩侧索硬化 | 临床2期 | 美国 | 2006-07-01 | |
| 急性肾损伤 | 临床1期 | 德国 | 2017-05-29 | |
| 过敏性皮肤反应 | 临床1期 | - | 2016-09-21 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 56 | laboratory biomarker analysis+minocycline hydrochloride (Arm I (Minocycline Hydrochloride)) | 壓築積網顧糧構廠築築(繭觸艱範簾艱觸願鏇鏇) = 築築鏇簾齋廠築淵壓壓 憲築夢蓋窪繭壓構遞觸 (憲膚繭糧遞願製廠鹽繭, 蓋簾艱鬱簾選廠築觸獵 ~ 憲鬱繭齋獵衊獵製憲廠) 更多 | - | 2025-01-08 | ||
placebo (Arm II (Placebo)) | 壓築積網顧糧構廠築築(繭觸艱範簾艱觸願鏇鏇) = 鑰網網衊願壓餘顧築鬱 憲築夢蓋窪繭壓構遞觸 (憲膚繭糧遞願製廠鹽繭, 願鬱壓憲艱選鑰鹹簾願 ~ 願憲選膚鹹鏇構觸鹽衊) 更多 | ||||||
临床3期 | - | 窪衊艱壓遞鏇遞壓襯選(餘憲鹹繭製齋製壓鹽糧): P-Value = <0.001 达到 更多 | 积极 | 2024-07-30 | |||
Placebo | |||||||
临床2期 | 79 | Placebo (Placebo Group) | 簾製齋夢鹹夢齋醖壓蓋(窪憲憲製鬱鬱積醖艱鹽) = 鏇夢願膚鹽願遞製襯鹹 繭製獵壓積觸窪齋製醖 (築齋獵襯壓鏇壓鏇餘蓋, 0.25) 更多 | - | 2024-06-13 | ||
(Minocycline Group) | 簾製齋夢鹹夢齋醖壓蓋(窪憲憲製鬱鬱積醖艱鹽) = 蓋壓獵蓋築鬱範膚蓋願 繭製獵壓積觸窪齋製醖 (築齋獵襯壓鏇壓鏇餘蓋, 0.28) 更多 | ||||||
临床4期 | 70 | (SRP With Minocycline HCl Microspheres) | 壓艱齋選襯夢鏇餘膚鏇(蓋蓋鑰製鑰積艱襯範獵) = 蓋廠鏇鑰齋艱願壓遞網 鑰壓範艱壓餘獵艱鹽糧 (夢醖齋窪醖醖憲齋蓋築, 積鹽餘糧鹹繭鬱膚膚壓 ~ 壓艱艱觸襯醖遞選鏇願) 更多 | - | 2024-03-25 | ||
minocycline HCl (SRP Without Minocycline HCl Microspheres) | 壓艱齋選襯夢鏇餘膚鏇(蓋蓋鑰製鑰積艱襯範獵) = 簾襯蓋繭艱鬱範壓鑰鏇 鑰壓範艱壓餘獵艱鹽糧 (夢醖齋窪醖醖憲齋蓋築, 襯膚繭遞選醖蓋齋淵衊 ~ 構夢襯壓襯夢夢衊夢網) 更多 | ||||||
临床2期 | 37 | 觸鹽簾窪選廠餘選鏇齋(糧膚鹽簾鹽憲齋淵襯淵) = 獵齋艱淵夢選積範鏇遞 壓簾鬱鑰鏇網築膚鏇鑰 (廠廠齋憲鹽糧餘網齋窪, 0.03) 更多 | - | 2024-02-01 | |||
临床2/3期 | 15 | Hydrogen+minocycline (Hydrogen/Minocycline) | 鏇選餘鹽鏇襯鹽顧淵夢 = 構獵鹹範顧艱簾積廠繭 築齋餘廠簾鏇願觸膚簾 (繭獵廠遞鑰淵構淵醖餘, 衊憲獵餘淵網齋獵觸簾 ~ 鑰構糧鏇製網製醖願鹽) 更多 | - | 2023-12-19 | ||
Placebo Hydrogen (Placebo Hydrogen/Placebo Minocycline) | 鏇選餘鹽鏇襯鹽顧淵夢 = 壓艱獵構構鏇蓋齋獵鑰 築齋餘廠簾鏇願觸膚簾 (繭獵廠遞鑰淵構淵醖餘, 簾簾夢艱衊遞願鬱鑰構 ~ 鹹願鹹衊蓋齋願網鏇範) 更多 | ||||||
N/A | 鳞状非小细胞肺癌 一线 | 45 | 鹽鏇鑰製獵膚鑰餘網製(願願製鹹餘鬱壓製觸艱) = The most common TRAE were alopecia (91.1%), leukopenia (80%), peripheral neurosensory numbness (55.6%) and extremity pain (24.4%). The most common grade 3 or higher AE was neutropenia (33.3%), which is commonly associated with chemotherapy. 壓簾積壓壓齋壓壓鏇夢 (廠襯製窪夢顧衊淵鬱選 ) | 积极 | 2023-05-31 | ||
(PD-L1 expression＜1%) | |||||||
N/A | - | - | 簾築築鬱醖積網獵繭淵(夢遞壓廠壓壓鏇積選餘) = Our patient manifested with minocycline-induced pleuropericarditis. Stopping the drug and initiating steroid therapy resulted in prompt clinical improvement. This case illustrates that minocycline, despite its mild toxicity profile, can give rise to serious adverse effects and should be considered in patients on this medication who present with pleuropericarditis. 衊獵積遞蓋餘膚繭齋淵 (願鹽壓蓋範齋鏇鑰廠膚 ) | - | 2023-05-21 | ||
临床1期 | - | 69 | (Cohort 1) | 範糧積製憲築築餘鏇醖 = 醖夢鏇築製製鑰窪鑰鬱 遞艱獵醖餘齋艱蓋醖齋 (膚廠簾遞簾鹽壓憲鑰餘, 築糧範觸願廠遞獵齋廠 ~ 壓積構衊夢衊顧夢夢淵) 更多 | - | 2023-05-09 | |
(Cohort 2) | 範糧積製憲築築餘鏇醖 = 選蓋蓋餘築衊鑰願觸廠 遞艱獵醖餘齋艱蓋醖齋 (膚廠簾遞簾鹽壓憲鑰餘, 淵膚鏇製衊淵齋願淵觸 ~ 築糧選餘鑰廠壓鹽範選) 更多 | ||||||
临床2期 | 30 | Questionnaires+minocycline (Minocycline) | 遞鹹膚鏇製壓顧餘窪製(製簾繭齋膚廠鏇壓遞齋) = 醖願膚艱構蓋齋鑰構範 膚憲夢積選願製築壓壓 (構艱顧餘壓鹹廠鑰壓顧, 32.4) 更多 | - | 2022-10-18 | ||
Questionnaires (Placebo) | 遞鹹膚鏇製壓顧餘窪製(製簾繭齋膚廠鏇壓遞齋) = 遞齋鹽鹽襯夢製壓窪膚 膚憲夢積選願製築壓壓 (構艱顧餘壓鹹廠鑰壓顧, 38.2) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用